文献速递甲状腺核医学骨显像与常规 SPECT

99mTc-MIBI SPECT/CT可作为甲状旁腺腺瘤射频消融成功的早期指标

SPECT/CT With 99mTc-MIBI as an Early Indicator of the Success of Radiofrequency Ablation of Parathyroid Adenomas.
PubMed 文献 · Clin Nucl Med · 2026-10-20

本文报道一例55岁高钙性原发性甲状旁腺功能亢进男性患者,术前99mTc-MIBI SPECT/CT定位右下甲状旁腺腺瘤,因拒绝手术行射频消融。术后6个月PTH轻度升高但钙渐进正常,随访SPECT/CT未见残留腺瘤摄取,正确预测延迟生化治愈,1年时PTH正常化。提示99mTc-MIBI SPECT/CT可能作为射频消融后早期疗效影像生物标志物。

要点

  • 术前99mTc-MIBI SPECT/CT可定位甲状旁腺腺瘤,指导射频消融。
  • 消融后6个月PTH轻度升高时,SPECT/CT无残留摄取可预测延迟生化治愈。
  • SPECT/CT可能作为射频消融后早期疗效影像标志物。

核心结论

  • 99mTc-MIBI SPECT/CT有潜力作为甲状旁腺腺瘤射频消融治疗后早期判断治疗成功的影像生物标志物。

研究设计与样本

  • 单例病例报道:55岁男性高钙性原发性甲状旁腺功能亢进患者,术前99mTc-MIBI SPECT/CT定位右下甲状旁腺腺瘤,因拒绝手术行射频消融,随访至1年。

主要发现

  • 射频消融后钙渐进正常化,6个月时PTH仍轻度升高。
  • 随访99mTc-MIBI SPECT/CT未见残留腺瘤摄取,正确预测延迟生化治愈。
  • 1年时PTH恢复正常。

临床怎么用

  • 对甲状旁腺腺瘤射频消融后PTH轻度升高的患者,可用99mTc-MIBI SPECT/CT评估有无残留腺瘤摄取,辅助判断是否延迟治愈。

局限性

  • 仅为单例病例报道,结论需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 55-year-old man with hypercalcemic primary hyperparathyroidism underwent preprocedural localization with 99mTc-MIBI SPECT/CT, demonstrating a right inferior parathyroid adenoma. As the patient refused surgery, radiofrequency ablation was performed. Calcium normalized progressively, while parathyroid hormone (PTH) levels remained mildly elevated at 6 months. Follow-up 99mTc-MIBI SPECT/CT showed no residual adenomatous uptake, correctly predicting delayed biochemical cure, with subsequent normalization of PTH at 1 year. This case highlights the potential value of 99mTc-MIBI SPECT/CT as an early imaging biomarker of therapeutic success after radiofrequency ablation in patients with persistent mild PTH elevation.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jiménez Hernando I, López Guerra A, Miguélez González M, et al. SPECT/CT With 99mTc-MIBI as an Early Indicator of the Success of Radiofrequency Ablation of Parathyroid Adenomas. Clin Nucl Med. 2026. PMID: 42912547. doi:10.1097/RLU.0000000000006694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。